Cirrhosis secondary prevention: Difference between revisions
Jump to navigation
Jump to search
Megan Merlo (talk | contribs) No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} {{AE}} {{RT}} | {{CMG}} {{AE}} {{RT}} | ||
==Overview== | ==Overview== | ||
Secondary prevention in patients with cirrhosis is aimed at preventing further damage | [[Prevention (medical)|Secondary prevention]] in patients with [[cirrhosis]] is aimed at preventing further damage to the [[liver]]. Avoidance of [[alcohol]] and other hepatotoxins, treatment of underlying [[chronic liver disease]] and [[Vaccination|immunization]] against [[Hepatitis|viral hepatitis]] for susceptible patients are key measures of [[Prevention (medical)|secondary prevention]] of [[cirrhosis]]. | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
* Abstinence from | * Abstinence from [[alcohol]] prevents further [[liver]] damage in patients with [[cirrhosis]]. | ||
* | * Vaccination against [[Hepatitis A]] and [[Hepatitis B|B]] help prevent superimposed insult to the cirrhotic [[liver]]. | ||
==Tertiary Prevention== | ==Tertiary Prevention== | ||
===Overview=== | ===Overview=== | ||
Tertiary prevention in patients with cirrhosis is aimed at preventing the complications that arise from cirrhosis, such as [[esophageal varices]], [[spontaneous bacterial peritonitis]], [[hepatorenal syndrome]] and [[portal vein thrombosis]]. | Tertiary prevention in [[Patient|patients]] with [[cirrhosis]] is aimed at preventing the complications that arise from [[cirrhosis]], such as [[esophageal varices]], [[spontaneous bacterial peritonitis]], [[hepatorenal syndrome]] and [[portal vein thrombosis]]. | ||
===Tertiary Prevention=== | ===Tertiary Prevention=== | ||
* Non-selective [[beta blockers]] reduce the risk of further bleeding from the [[esophageal varices]]. | * Non-selective [[beta blockers]] reduce the risk of further [[bleeding]] from the [[esophageal varices]]. | ||
* Judicious use of diuretics and prophylactic antibiotics | * Judicious use of [[Diuretic|diuretics]] and [[Prophylaxis|prophylactic]] [[Antibiotic|antibiotics]] prevent [[spontaneous bacterial peritonitis]]. | ||
* Avoiding vigorous diuresis and nephrotoxic drugs help to prevent [[hepatorenal syndrome]]. | * Avoiding vigorous [[diuresis]] and [[nephrotoxic drugs]] help to prevent [[hepatorenal syndrome]]. | ||
* [[Enoxaparin]], a low molecular weight heparin, | * [[Enoxaparin]], a [[low molecular weight heparin]], is effective in the prevention of [[portal vein thrombosis]] in [[Patient|patients]] with [[cirrhosis]]. | ||
==References== | ==References== | ||
Revision as of 18:33, 5 December 2017
|
Cirrhosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case studies |
|
Cirrhosis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Cirrhosis secondary prevention |
|
Risk calculators and risk factors for Cirrhosis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]
Overview
Secondary prevention in patients with cirrhosis is aimed at preventing further damage to the liver. Avoidance of alcohol and other hepatotoxins, treatment of underlying chronic liver disease and immunization against viral hepatitis for susceptible patients are key measures of secondary prevention of cirrhosis.
Secondary Prevention
- Vaccination against Hepatitis A and B help prevent superimposed insult to the cirrhotic liver.
Tertiary Prevention
Overview
Tertiary prevention in patients with cirrhosis is aimed at preventing the complications that arise from cirrhosis, such as esophageal varices, spontaneous bacterial peritonitis, hepatorenal syndrome and portal vein thrombosis.
Tertiary Prevention
- Non-selective beta blockers reduce the risk of further bleeding from the esophageal varices.
- Judicious use of diuretics and prophylactic antibiotics prevent spontaneous bacterial peritonitis.
- Avoiding vigorous diuresis and nephrotoxic drugs help to prevent hepatorenal syndrome.
- Enoxaparin, a low molecular weight heparin, is effective in the prevention of portal vein thrombosis in patients with cirrhosis.